FX06
Acute Respiratory Distress Syndrome (ARDS)
Key Facts
About F4 Pharma
F4 Pharma is an Austrian preclinical/clinical-stage biotech targeting serious conditions driven by endothelial dysfunction and capillary leak, such as ARDS and Clarkson disease. Its core technology is a novel anti-inflammatory peptide platform, with its most advanced candidate, FX06, entering clinical trials for ARDS. The company operates as a private, pre-revenue entity aiming to address significant unmet medical needs in critical care and orphan diseases.
View full company profileAbout F4 Pharma
F4 Pharma is an Austrian preclinical/clinical-stage biotech targeting serious conditions driven by endothelial dysfunction and capillary leak, such as ARDS and Clarkson disease. Its core technology is a novel anti-inflammatory peptide platform, with its most advanced candidate, FX06, entering clinical trials for ARDS. The company operates as a private, pre-revenue entity aiming to address significant unmet medical needs in critical care and orphan diseases.
View full company profileTherapeutic Areas
Other Acute Respiratory Distress Syndrome (ARDS) Drugs
| Drug | Company | Phase |
|---|---|---|
| MultiStem | Athersys | Phase 3 |
| BXT-25 | BioXyTran | Preclinical |
| Bioengineered Surfactant Program | BioSuperior | Pre-clinical |
| AVM0703 | AVM Biotechnology | Pre-clinical / Research |
| ACE2v2-Fc | Cyrus Biotechnology | Preclinical |
| GEn-1124 | GEn1E Lifesciences | Phase 2 |
| AZM-152 | Azome Therapeutics | Pre-clinical |
| Zelpultide Alfa | Airway Therapeutics | Pre-clinical/Research |
| ALT-100 mAb | Aqualung Therapeutics | Phase 2a |
| RP-323 | PhorMed | Phase 2 |
| Research Grant: Effect of volatile sedation on spontaneous breathing in ARDS | Sedana Medical | Investigator-Initiated Trial |
| Research Grant: Effects of sevoflurane on lung water in ARDS | Sedana Medical | Investigator-Initiated Trial |